StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Keros Therapeutics's EV/EBITDA was 0.8× on Jan 30, 2026.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Jan 30, 20260.8×−2.3
2025Dec 31, 20253.1×–

More Keros Therapeutics figures

See a number that looks wrong?